Drugs / LDE255
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02323139 | Feb 2015 → Jan 2018 | myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LDE255 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02323139 ↗ |
| Route | Oral | “Oral Smoothened Antagonist LDE255” NCT02323139 ↗ |